ARS Pharmaceuticals director granted 30,000 stock options

ARS Pharmaceuticals director Brent L. Saunders received a grant of stock options covering 30,000 shares of common stock.

Rhea-AI Filing Summary

ARS Pharmaceuticals director Brent L. Saunders received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.54 per share and expire on June 23, 2036. They vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders.

Insider Trade Summary

Grant/Award: 30,000 shares

Grant/Award 1 txn

Insider SAUNDERS BRENT L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 30,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

Key Figures

Option grant size: 30,000 options Exercise price: $10.54 per share Underlying shares: 30,000 shares +3 more

6 metrics

Option grant size 30,000 options Stock Option (right to buy) granted to director Brent L. Saunders

Exercise price $10.54 per share Exercise price of options on ARS Pharmaceuticals common stock

Underlying shares 30,000 shares Common stock underlying the stock option grant

Expiration date June 23, 2036 Option expiration for director’s stock option grant

Vesting date Earlier of June 24, 2027 or 2027 annual meeting Full vesting schedule for the stock option grant

Post-grant derivative holdings 30,000 options Total derivative securities following this transaction

Key Terms

Stock Option (right to buy), Grant, award, or other acquisition, annual meeting of stockholders

3 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

annual meeting of stockholders financial

"vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ARS Pharmaceuticals (SPRY) director Brent Saunders receive in this Form 4?

Brent L. Saunders received a grant of stock options on 30,000 ARS Pharmaceuticals common shares. These options were awarded as compensation and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of Brent Saunders’ ARS Pharmaceuticals options?

The stock options have an exercise price of $10.54 per share. This means Saunders can purchase up to 30,000 ARS Pharmaceuticals shares at $10.54, regardless of the market price when he chooses to exercise, once vested.

When do Brent Saunders’ ARS Pharmaceuticals (SPRY) options vest?

The options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders. Vesting must occur before Saunders can exercise the options to buy ARS Pharmaceuticals common stock.

How many ARS Pharmaceuticals shares are covered by Brent Saunders’ new options?

The grant covers 30,000 underlying shares of ARS Pharmaceuticals common stock. After this award, the filing shows 30,000 derivative securities owned, all tied to this single stock option grant reported in the Form 4.

When do Brent Saunders’ ARS Pharmaceuticals options expire?

The options expire on June 23, 2036 if not exercised earlier. After that date, Saunders will no longer be able to buy ARS Pharmaceuticals shares at the fixed $10.54 exercise price from this option grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/26/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SAUNDERS BRENT L

(Last) (First) (Middle)

C/O ARS PHARMACEUTICALS, INC.

11682 EL CAMINO REAL, SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARS Pharmaceuticals, Inc. [ SPRY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.54	06/24/2026		A		30,000		(1)	06/23/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.

	/s/ Kathleen Scott, Attorney-in-Fact	06/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)